Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shejil Kumar

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Endocrinology, Diabetes & Metabolism Case Reports|January 17, 2023
Hypercalcaemia secondary to hypophysitis and cortisol deficiency: another immunotherapy-related adverse eventSamuel R Miller, Shejil Kumar, Alexander Yuile, et al.
International Journal of Cardiology|February 29, 2016
The effect of N-acetylcysteine on the incidence of contrast-induced kidney injury: A systematic review and trial sequential analysisNelson Wang, Pierre Qian, Shejil Kumar, et al.
JBMR Plus|December 25, 2025
Burosumab in adults with X-linked hypophosphatemia: real-world experience from a retrospective study in SydneyShejil Kumar, Christian M Girgis, Brian Tran, et al.
Current Osteoporosis Reports|April 10, 2025
Exercise for Postmenopausal Bone Health - Can We Raise the Bar?Shejil Kumar, Cassandra Smith, Roderick J Clifton-Bligh, et al.
Bone Reports|December 4, 2025
Combination or sequential teriparatide for osteoporosis treatment in denosumab-users: real-world bone mineral density outcomesShejil Kumar, Courtney Streeter, Michelle M McDonald, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 9, 2025
Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fracturesShejil Kumar, Mawson Wang, Albert S Kim, et al.
Pathology|January 20, 2026
Heritable metabolic bone disorders: a guide to current genetic testing and clinical management for adult endocrinologistsShejil Kumar, Emma L Duncan, Lisa Hayes, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 5, 2024
A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosisShejil Kumar, Matti L Gild, Michelle M McDonald, et al.
The Lancet. Diabetes & Endocrinology|December 22, 2019
Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participantsNelson Wang, Jordan Fulcher, Nishan Abeysuriya, et al.
BMJ Open|August 24, 2024
Study protocol for the ROLEX-DUO randomised placebo-controlled trial: ROmosozumab Loaded with EXercise - DUal effects on bone and muscle in postmenopausal Osteoporosis and OsteopeniaShejil Kumar, Belinda R Beck, Liza Nery, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Endocrinology, Diabetes & Metabolism Case Reports|January 17, 2023
Hypercalcaemia secondary to hypophysitis and cortisol deficiency: another immunotherapy-related adverse eventSamuel R Miller, Shejil Kumar, Alexander Yuile, et al.
International Journal of Cardiology|February 29, 2016
The effect of N-acetylcysteine on the incidence of contrast-induced kidney injury: A systematic review and trial sequential analysisNelson Wang, Pierre Qian, Shejil Kumar, et al.
JBMR Plus|December 25, 2025
Burosumab in adults with X-linked hypophosphatemia: real-world experience from a retrospective study in SydneyShejil Kumar, Christian M Girgis, Brian Tran, et al.
Current Osteoporosis Reports|April 10, 2025
Exercise for Postmenopausal Bone Health - Can We Raise the Bar?Shejil Kumar, Cassandra Smith, Roderick J Clifton-Bligh, et al.
Bone Reports|December 4, 2025
Combination or sequential teriparatide for osteoporosis treatment in denosumab-users: real-world bone mineral density outcomesShejil Kumar, Courtney Streeter, Michelle M McDonald, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 9, 2025
Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fracturesShejil Kumar, Mawson Wang, Albert S Kim, et al.
Pathology|January 20, 2026
Heritable metabolic bone disorders: a guide to current genetic testing and clinical management for adult endocrinologistsShejil Kumar, Emma L Duncan, Lisa Hayes, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 5, 2024
A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosisShejil Kumar, Matti L Gild, Michelle M McDonald, et al.
The Lancet. Diabetes & Endocrinology|December 22, 2019
Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participantsNelson Wang, Jordan Fulcher, Nishan Abeysuriya, et al.
BMJ Open|August 24, 2024
Study protocol for the ROLEX-DUO randomised placebo-controlled trial: ROmosozumab Loaded with EXercise - DUal effects on bone and muscle in postmenopausal Osteoporosis and OsteopeniaShejil Kumar, Belinda R Beck, Liza Nery, et al.
Pageof 3